A model developed by LMU biophysicists demonstrates how biological processes form the convoluted internal architecture of the ...

Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a ...

CAR-T cells are, in essence, T-lymphocytes equipped with a next-generation membrane receptor: a structure specifically designed to recognize and attack tumor cells with a precision and sensitivity ...

Despite the remarkable efficacy of CAR-T cell therapies to treat certain blood ... The spongelike structure is also sprinkled with antibodies to activate the T cells and the cytokine IL-2 to ...

Peripheral T-cell lymphoma is a rare and aggressive type of cancer that affects mature T cells. Learn more ... research from 2020 mentions that changes in the DNA’s structure causing ...

The T cells that protect us from infections and cancer, they say, have an ignition switch. They also have gas pedals and brakes. How immunologists, like good molecular mechanics, deciphered what makes ...

Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of non-Hodgkin's lymphomas and is a rare but aggressive form of T-cell lymphoma that usually occurs in children and young adults.

SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune ...